In addition, ipilimumab plus nivolumab has also been indicated for the first-line treatment of patients with non-small-cell lung carcinoma (NSCLC) whose tumors express PD-L1 (≥ 1%) [47], and also for malignant pleural mesothelioma (MPM) [48]. Here, CD274 is linked to non-small cell lung carcinoma.